
CLAIMS

WHAT IS CLAIMED IS:

1. A Drug-Linker of Formula (I-B):




Formula (I-B)





or a pharmaceutically acceptable salt thereof, wherein;


D is selected from a Drug unit;

X is selected from CH and N;


Y is ;


S^3 is absent;

K^1 is selected from: , , , , , ,



,



, wherein each R^6 is selected from -OH, $-NH_2$, and , and each j is selected from 1 to 30.

2. The Drug-Linker or salt of claim 1, wherein X is CH.


3. The Drug-Linker or salt of claim 2, wherein D is a selected from a cytotoxic agent, and an immune modulatory agent.


4. The Drug-Linker or salt of claim 2, wherein D is a selected from a cytotoxic agent.

5. The Drug-Linker or salt of claim 2, wherein D is selected from tubulin disrupting agents, topoisomerase inhibitors, DNA minor groove binders, and DNA alkylating agents.


6. The Drug-Linker or salt of claim 2, wherein D is selected from MMAE, MMAF, and exatecan.


7. The Drug-Linker or salt of claim 2, wherein D is exatecan.

8. The Drug-Linker or salt of claim 1, wherein K^1 is selected from ,




,










,





,





,



,


,

,

,



, and

.




9. The Drug-Linker or salt of claim 5, wherein K^1 is selected from



,

,

, and


.


10. The Drug-Linker or salt of claim 1, wherein the Drug-Linker is selected from:


,



,

,

,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




, and




.


11. The Drug-Linker or salt of claim 1, wherein the Drug-Linker is selected from:




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




, and



.


12. A conjugate of Formula (A-2):



Formula (A-2)







or a pharmaceutically acceptable salt thereof, wherein;

D is selected from a Drug unit;

Y is ;

S^3 is absent;

L is a Targeting Unit, wherein the Targeting unit is selected from an antibody or an antigen-binding portion thereof;

K^1 is selected from: , , , , , , wherein each R^6 is selected from -OH, $-NH_2$, and , and each j is selected from 1 to 30.

13. The conjugate or salt of claim 12, wherein X is CH.













14. The conjugate or salt of claim 12, wherein D is a selected from a cytotoxic agent, and an immune modulatory agent.





15. The conjugate or salt of claim 12, wherein D is a selected from a cytotoxic agent.

16. The conjugate or salt of claim 12, wherein D is selected from tubulin disrupting agents, topoisomerase inhibitors, DNA minor groove binders, and DNA alkylating agents.


17. The conjugate or salt of claim 12, wherein D is selected from MMAE, MMAF, and exatecan.


18. The conjugate or salt of claim 12, wherein D is exatecan.


19. The conjugate or salt of claim 12, wherein K^1 is selected from , , , , , , , , , , , and .


20. The conjugate or salt of claim 16, wherein K^1 is selected from , , , and .


21. The conjugate or salt of claim 12, wherein the conjugate is represented by


















wherein DAR is a drug to antibody ratio, wherein each DAR is from about 2 to about 8.

22. The conjugate or salt of claim 12, wherein the conjugate is represented by



L
DAR


L
DAR


L
DAR



, and



,

wherein DAR is a drug to antibody ratio, wherein each DAR is from about 2 to about 8.

23. The conjugate or salt of claim 12, wherein:

the antibody or antigen-binding portion thereof has a heavy chain, wherein the heavy chain is SEQ ID NO:1; and a light chain, wherein the light chain is SEQ ID NO:2;

the antibody or antigen-binding portion thereof has a heavy chain, wherein the heavy chain is SEQ ID NO:3; and a light chain, wherein the light chain is SEQ ID NO:4;

the antibody or antigen-binding portion thereof is UC-961; or

the antibody or antigen-binding portion thereof is a ROR2 antibody.

24. The conjugate or salt of claim 12, wherein the antibody or antigen-binding portion thereof has a heavy chain, wherein the heavy chain is SEQ ID NO:1; and a light chain, wherein the light chain is SEQ ID NO:2.

25. The conjugate or salt of claim 12, wherein the antibody or antigen-binding portion thereof has a heavy chain, wherein the heavy chain is SEQ ID NO:3; and a light chain, wherein the light chain is SEQ ID NO:4.

26. The conjugate or salt of claim 12, wherein the antibody or antigen-binding portion thereof is UC-961.

27. The conjugate or salt of claim 12, wherein the antibody or antigen-binding portion thereof is a ROR2 antibody.

28. A pharmaceutical composition comprising a conjugate of any one of claims 12 to 27, and a pharmaceutically acceptable excipient.

29. Use of a conjugate of any one of claims 12 to 27 or a pharmaceutical composition of claim 28 in the manufacture of a medicament for treating a disease or disorder, wherein the disease or disorder is a cancer.

30. The use of claim 29, wherein the cancer is selected from: cancers of the head and neck which include tumors of the head, neck, nasal cavity, paranasal sinuses, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx, salivary glands, and paragangliomas; cancers of the liver and biliary tree, particularly hepatocellular carcinoma; intestinal cancers, particularly colorectal cancer; ovarian cancer; small cell and non-small cell lung cancer (SCLC and NSCLC); breast cancer sarcomas, such as fibrosarcoma, malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, leiomysosarcoma, neurofibrosarcoma, osteosarcoma, synovial sarcoma, liposarcoma, and alveolar soft part sarcoma; leukemias such as acute promyelocytic leukemia (APL), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML); neoplasms of the central nervous systems, particularly brain cancer; multiple myeloma (MM), lymphomas such as Hodgkin's lymphoma, lymphoplasmacytoid lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, mantle cell lymphoma, B-lineage large cell lymphoma, Burkitt's lymphoma, and T-cell anaplastic large cell lymphoma.